Related Experiment Video
Updated: Jan 1, 2026
07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.3K
Frailty Syndromes in Persons With Cerebrovascular Disease: A Systematic Review and Meta-Analysis
Katie Palmer1, Davide L Vetrano1,2, Luca Padua1
1Department of Geriatrics, Centro Medicina dell'Invecchiamento, Università Cattolica del Sacro Cuore, Rome, Italy.
Frontiers in Neurology
|December 19, 2019
Summary
Frailty and prefrailty are common in stroke patients, with frailty being twice as prevalent compared to the general population. This highlights the need for frailty assessment in stroke survivors to understand its impact on prognosis.
Area of Science:
- Gerontology
- Neurology
- Public Health
Background:
- Frailty significantly impacts chronic disease prognosis and treatment.
- Frailty is increasingly recognized as a factor in cerebrovascular diseases, particularly stroke.
- The precise relationship between frailty and stroke requires systematic investigation.
Approach:
- A systematic review and meta-analysis were conducted following PRISMA guidelines.
- Literature search across PubMed, Web of Science, and Embase (2002-2019).
- Pooled estimates derived using random-effects models and Mantel-Haenszel weighting, with heterogeneity and bias assessed.
Key Points:
- 18 studies (n=48,009) were included, focusing solely on stroke and frailty syndromes.
- Pooled prevalence of prefrailty and frailty in stroke patients was 49% and 22%, respectively.
- Frailty was found to be twice as prevalent in stroke patients (OR=2.32).
Conclusions:
- Frailty and prefrailty are highly prevalent in individuals with stroke.
- Findings suggest routine frailty assessment in post-stroke survivors is clinically relevant.
- Further high-quality, longitudinal research is needed to clarify the temporal relationship and explore other cerebrovascular diseases.
Related Concept Videos
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
289
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
289
01:17Ischemic Heart Disease: Overview
2.7K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
2.7K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
157
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
157
01:26Atherosclerosis III: Management
284
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
284
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
401
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
401
01:30Peripheral Artery Disease I: Introduction
258
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
258